GlassScriptPhysician profile
Madho K Sharma
NPI 1134111883
$3,845.79
in general payments reported to CMS, 2019-2025
22 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $812 · 2021: $288 · 2022: $426 · 2023: $489 · 2024: $1,088 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $634.56 | 2019-2025 | Arexvy |
| Vital Connect, INC | $387.11 | 2024-2025 | Vitalpatch Rtm |
| Janssen Pharmaceuticals, INC | $375.89 | 2020-2024 | Xarelto |
| Novo Nordisk INC | $288.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.11 | 2020-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.43 | 2019-2022 | |
| Lilly USA, LLC | $164.59 | 2019-2021 | |
| Heartflow, INC. | $147.94 | 2024 | |
| Novartis Pharmaceuticals Corporation | $136.75 | 2024 | |
| Cvrx, INC. | $135.38 | 2023 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $124.94 | 2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $124.61 | 2019 | |
| Abbott Laboratories | $124.30 | 2023 | Aveir |
| Phathom Pharmaceuticals, INC. | $121.33 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $105.10 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $104.29 | 2024 | |
| Amgen INC. | $104.15 | 2023 | Repatha |
| Amarin Pharma, INC. | $95.48 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $91.69 | 2019-2021 | |
| Pfizer INC. | $42.82 | 2020-2022 | |
| Genzyme Corporation | $29.49 | 2021 | |
| Qol Medical, LLC | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madho Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.